Share on LinkedInShare on LinkedIn

ARTICLE · 24 NOVEMBER 2023

PMPRB Publishes Scoping Paper For The Consultations On The Board's Guidelines To Streamline Policy Roundtable

The Patented Medicines Prices Review Board ("PMPRB") is responsible for ensuring that the prices of patented medicines in Canada are not excessive.

CanadaIntellectual Property

The Patented Medicines Prices Review Board ("PMPRB") is responsible for ensuring that the prices of patented medicines in Canada are not excessive. In fulfilling this mandate, Guidelines issued in 2010 provided transparency to the PMPRB's approach to patented medicines price monitoring, including the price review process and investigations, and were meant to be read in conjunction with the Patent Act and Regulations.

With the recent coming into force of amendments to the Patented Medicines Regulations in July 2022, the PMPRB is in the process of updating the Guidelines. As part of the updating process, the PMPRB will host a Policy Roundtable on December 5 (English) and 6 (French) during which interested parties are invited to voice their opinions and concerns regarding the future Guidelines.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from